The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Commentary/Response Threads

• McCarthy, EM, Sutton, E, Nesbit, S, Parker, B, Jayne, D, Griffiths, B, Isenberg, DA, Rahman, A, Gordon, C, D’Cruz, DP, Rhodes, B, Lanyon, P, Vital, EM, Yee, C-S, Edwards, CJ, Teh, L-S, Akil, M, McHugh, NJ, Zoma, A, Bruce, IN and British Isles Lupus Assessment Group Biologics Register The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (deposited 25 Sep 2018 15:05) [Currently Displayed]
  • McCarthy, EM, Sutton, E, Nesbit, S, Parker, B, Jayne, D, Griffiths, B, Isenberg, DA, Rahman, A, Gordon, C, D’Cruz, DP, Rhodes, B, Lanyon, P, Vital, EM, Yee, C-S, Edwards, CJ, Teh, L-S, Akil, M, McHugh, NJ, Zoma, A, Bruce, IN and British Isles Lupus Assessment Group Biologics Register Corrigendum: The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (deposited 25 Sep 2018 14:53)